FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 180 filers reported holding FATE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $589,050 | +3.9% | 123,750 | +24.4% | 0.00% | 0.0% |
| Q1 2023 | $566,865 | -14.4% | 99,450 | +51.5% | 0.00% | 0.0% |
| Q4 2022 | $662,409 | +45.9% | 65,650 | +224.2% | 0.00% | 0.0% |
| Q3 2022 | $454,000 | -9.6% | 20,250 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $502,000 | -36.1% | 20,250 | 0.0% | 0.00% | -50.0% |
| Q1 2022 | $785,000 | -33.8% | 20,250 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $1,185,000 | +93.9% | 20,250 | +187.7% | 0.00% | +100.0% |
| Q2 2021 | $611,000 | -63.1% | 7,039 | -65.0% | 0.00% | -75.0% |
| Q1 2021 | $1,658,000 | -44.3% | 20,117 | -38.5% | 0.00% | -42.9% |
| Q4 2020 | $2,976,000 | +52.2% | 32,734 | -33.1% | 0.01% | +40.0% |
| Q3 2020 | $1,955,000 | +998.3% | 48,922 | +844.1% | 0.01% | – |
| Q2 2020 | $178,000 | +54.8% | 5,182 | 0.0% | 0.00% | – |
| Q1 2020 | $115,000 | -58.8% | 5,182 | -63.7% | 0.00% | -100.0% |
| Q4 2019 | $279,000 | – | 14,273 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $7,163,616 | 2.64% |
| Redmile Group, LLC | 13,124,427 | $27,823,785 | 1.32% |
| Monaco Asset Management SAM | 1,847,944 | $3,917,641 | 1.16% |
| Casdin Capital, LLC | 2,050,000 | $4,346,000 | 0.48% |
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $1,484,000 | 0.21% |
| GCM Grosvenor Holdings, LLC | 495,916 | $1,051,342 | 0.21% |
| Nebula Research & Development LLC | 163,617 | $346,868 | 0.18% |
| Bellevue Group AG | 4,851,579 | $10,285,347 | 0.17% |
| Bruce & Co., Inc. | 200,000 | $424,000 | 0.14% |
| XTX Topco Ltd | 192,920 | $408,990 | 0.07% |